Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Orchestra BioMed Holdings (OBIO) EBIT (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed EBIT for 4 consecutive years, with -$20.3 million as the latest value for Q3 2025.

  • On a quarterly basis, EBIT fell 24.3% to -$20.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$75.2 million, a 25.18% decrease, with the full-year FY2024 number at -$64.3 million, down 24.84% from a year prior.
  • EBIT was -$20.3 million for Q3 2025 at Orchestra BioMed Holdings, down from -$19.3 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$813415.0 in Q3 2022 to a low of -$20.3 million in Q3 2025.
  • A 4-year average of -$13.2 million and a median of -$14.4 million in 2024 define the central range for EBIT.
  • Peak YoY movement for EBIT: tumbled 1685.56% in 2023, then dropped 12.52% in 2024.
  • Orchestra BioMed Holdings' EBIT stood at -$9.8 million in 2022, then dropped by 26.99% to -$12.5 million in 2023, then plummeted by 33.62% to -$16.7 million in 2024, then decreased by 21.8% to -$20.3 million in 2025.
  • Per Business Quant, the three most recent readings for OBIO's EBIT are -$20.3 million (Q3 2025), -$19.3 million (Q2 2025), and -$18.9 million (Q1 2025).